CNS Pharmaceuticals, Inc. (CNSP) shareholders
Close on Nov 17, 2026Market cap $6.07MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Cortice Biosciences, Inc. | 573,368 | 5.70% | 13D (active) | Jul 29, 2024 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 561,148 | 9.99% | 13G (passive) | Jun 30, 2025 |
| Jon M. Plexico Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine Capital, L.P. (9.90%) and 1 more | 159,790 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Neil Shahrestani Joint filing with Ikarian Capital, LLC (9.90%) | 147,290 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Stonepine Capital Management, LLC Joint filing with Stonepine Capital, L.P. (7.90%), Stonepine GP, LLC (7.90%) and 1 more | 48,827 | 7.90% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CNSP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 135,830 | 9.29% | $649.27K | +90,000 | 0.07% |
| ADAR1 Capital Management, LLC | 70,000 | 4.79% | $334.60K | New | 0.02% |
| Stonepine Capital Management, LLC | 41,573 | 2.84% | $198.72K | −19,427 | 0.11% |
| Boothbay Fund Management, LLC | 13,524 | 0.93% | $64.65K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 10,226 | 0.70% | $48.88K | New | 0.00% |
| Vanguard Capital Management LLC | 6,993 | 0.48% | $33.43K | New | 0.00% |
| UBS Group AG | 1,461 | 0.10% | $6.98K | +732 | 0.00% |
| Tower Research Capital LLC (TRC) | 799 | 0.05% | $3.82K | −511 | 0.00% |
| Barclays PLC | 19 | 0.00% | $91 | New | 0.00% |
| Barrett & Company, Inc. | 8 | 0.00% | $38 | – | 0.00% |
| Danske Bank A/S | 1 | 0.00% | $5 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 11 | 0M | 19.2% | 4 / 2 | 2 / 4 | 0M | 0M |
| Q1 2026 | 11 | 0M | 10.0% | 4 / 2 | 0 / 2 | 0M | 0M |
| Q4 2025 | 9 | 0M | 8.5% | 3 / 1 | 1 / 2 | 0M | 0M |
| Q3 2025 | 8 | 0M | 1.7% | 8 / 0 | 0 / 1 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held CNSP in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CNSP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 6,993 | 0.48% | $33.43K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 6,736 | 0.46% | $36.64K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 555 | 0.04% | $3.02K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -49 | -0.00% | -$234 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John M. Climaco | Chief Executive Officer, Director | 215,676 | 14.76% | Nov 19, 2025 |
| Rami Levin | CEO and President | 4,750 | 0.33% | Aug 18, 2026 |
| Eric Faulkner | Chief Technology Officer | – | – | Mar 4, 2026 |
| Steve O'Loughlin | Chief Financial Officer | – | – | Mar 4, 2026 |
| Christopher Downs | Chief Financial Officer | 103,438 | 7.08% | Nov 19, 2025 |
| Michal Fisher | Director | 2,000 | 0.14% | Aug 18, 2026 |
| Faith L. Charles | Director | 7,100 | 0.49% | May 20, 2026 |
| Jeffry R. Keyes | Director | 11,100 | 0.76% | Nov 19, 2025 |
| Bettina M. Cockroft | Director | – | – | Nov 19, 2025 |
| Amy Mahery | Director | – | – | Nov 19, 2025 |
| Jerzy Gumulka | Director | 43,006 | 2.94% | Nov 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rami Levin CEO and President | Aug 14, 2026 | Option exercise | −4,750 | – | – | 4,750 |
| Michal Fisher Director | May 18, 2026 | Buy | +2,000 | $5.00 | $10.00K | 2,000 |
| Faith L. Charles Director | May 18, 2026 | Buy | +7,100 | $4.79 | $34.01K | 7,100 |
| Carl Anthony Evans Director | Feb 1, 2024 | Buy | +33,333 | $0.30 | $10.00K | 33,458 |
| Christopher Downs Chief Financial Officer | Feb 1, 2024 | Buy | +66,666 | $0.30 | $20.00K | 103,438 |
| Jerzy Gumulka Director | Feb 1, 2024 | Buy | +33,333 | $0.30 | $10.00K | 43,006 |
| John M. Climaco Chief Executive Officer, Director | Feb 1, 2024 | Buy | +166,666 | $0.30 | $50.00K | 215,676 |
| Christopher Downs Chief Financial Officer | Aug 22, 2023 | Buy | +27,000 | $1.27 | $34.29K | 36,772 |
| John M. Climaco Chief Executive Officer, Director | Aug 16, 2023 | Buy | +2,750 | $1.80 | $4.95K | 49,010 |
| Christopher Downs Chief Financial Officer | Apr 28, 2023 | Option exercise | +521 | – | – | 9,772 |
| John M. Climaco Chief Executive Officer, Director | Apr 28, 2023 | Option exercise | +1,250 | – | – | 46,260 |
| Jerzy Gumulka Director | Apr 19, 2023 | Buy | +2,500 | $1.70 | $4.25K | 9,673 |
| Christopher Downs Chief Financial Officer | Apr 17, 2023 | Buy | +3,100 | $3.20 | $9.92K | 9,251 |
| John M. Climaco Chief Executive Officer, Director | Apr 12, 2023 | Buy | +15,000 | $0.69 | $10.35K | 45,010 |
| Jerzy Gumulka Director | Apr 10, 2023 | Buy | +7,173 | $0.74 | $5.31K | 7,173 |
| Waldemar Priebe 10% owner | Mar 28, 2023 | Sale(10b5-1 plan) | −10,000 | $1.04 | $10.40K | 156,807 |
| Waldemar Priebe 10% owner | Mar 27, 2023 | Sale(10b5-1 plan) | −5,000 | $1.09 | $5.45K | 166,807 |
| Waldemar Priebe 10% owner | Mar 24, 2023 | Sale(10b5-1 plan) | −5,000 | $1.08 | $5.40K | 171,807 |
| Waldemar Priebe 10% owner | Mar 23, 2023 | Sale(10b5-1 plan) | −10,000 | $1.08 | $10.80K | 176,807 |
| Waldemar Priebe 10% owner | Mar 22, 2023 | Sale(10b5-1 plan) | −5,000 | $1.08 | $5.40K | 186,807 |
| Waldemar Priebe 10% owner | Mar 21, 2023 | Sale(10b5-1 plan) | −5,000 | $1.10 | $5.50K | 191,807 |
| Waldemar Priebe 10% owner | Mar 20, 2023 | Sale(10b5-1 plan) | −5,000 | $1.08 | $5.40K | 196,807 |
| Waldemar Priebe 10% owner | Mar 17, 2023 | Sale(10b5-1 plan) | −5,000 | $1.13 | $5.65K | 201,807 |
| Waldemar Priebe 10% owner | Mar 16, 2023 | Sale(10b5-1 plan) | −5,000 | $1.24 | $6.20K | 206,807 |
| Waldemar Priebe 10% owner | Mar 15, 2023 | Sale(10b5-1 plan) | −5,000 | $1.22 | $6.10K | 211,807 |
| Waldemar Priebe 10% owner | Mar 14, 2023 | Sale(10b5-1 plan) | −5,000 | $1.35 | $6.75K | 216,807 |
| Waldemar Priebe 10% owner | Mar 13, 2023 | Sale(10b5-1 plan) | −5,000 | $1.30 | $6.50K | 221,807 |
| Waldemar Priebe 10% owner | Mar 10, 2023 | Sale(10b5-1 plan) | −5,000 | $1.29 | $6.45K | 226,807 |
| Waldemar Priebe 10% owner | Dec 9, 2022 | Sale(10b5-1 plan) | −2,798 | $2.43 | $6.80K | 231,807 |
| Waldemar Priebe 10% owner | Dec 8, 2022 | Sale(10b5-1 plan) | −5,500 | $2.40 | $13.20K | 234,605 |
| Waldemar Priebe 10% owner | Dec 7, 2022 | Sale(10b5-1 plan) | −5,500 | $2.46 | $13.53K | 240,105 |
| Waldemar Priebe 10% owner | Dec 6, 2022 | Sale(10b5-1 plan) | −5,500 | $2.47 | $13.59K | 245,605 |
| Christopher Downs Chief Financial Officer | Mar 11, 2022 | Award | +33,000 | $0.31 | $10.23K | 184,500 |
| Carl Anthony Evans Director | Mar 8, 2022 | Award | +3,750 | $0.27 | $1.01K | 3,750 |
| Jeffry R. Keyes Director | Mar 7, 2022 | Award | +11,100 | $0.30 | $3.33K | 11,100 |
| John M. Climaco Chief Executive Officer, Director | Mar 7, 2022 | Award | +35,000 | $0.28 | $9.80K | 940,298 |
| Christopher Downs Chief Financial Officer | Dec 6, 2021 | Buy | +5,000 | $0.94 | $4.70K | 151,500 |
| Christopher Downs Chief Financial Officer | Nov 19, 2021 | Buy | +4,500 | $1.15 | $5.18K | 146,500 |
| John M. Climaco Chief Executive Officer, Director | Nov 16, 2021 | Award | +5,000 | $1.28 | $6.40K | 905,298 |
| Christopher Downs Chief Financial Officer | Aug 24, 2020 | Buy | +142,000 | $2.04 | $289.68K | 142,000 |
| Waldemar Priebe 10% owner | May 5, 2020 | Other | −1,495,867 | – | – | 7,533,133 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CNS Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,534 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?